REVIEW ARTICLE C. Michele Burnison, Stephen Lim; ONCOLOGY Vol. 26 No. 4 In this article, we endeavor to clarify the role of radiation therapy and chemotherapy in the treatment of ATC; we note important contributions of the historical literature, and we review more contemporary strategies adopted by several renowned institutions.
REVIEW ARTICLE Michaela J. Higgins, Arlene Forastiere, Shanthi Marur; ONCOLOGY Vol. 23 No. 9 This review highlights novel targeted agents for the treatment of differentiated and medullary thyroid cancers being studied at this time, and the results of recently published trials.
In part 2, we address risk assessment and staging, findings that suggest the presence of aggressive tumors, recurrent/metastatic disease, and treatment with chemotherapy and external-beam radiotherapy. Experimental treatments utilizing molecular targets, redifferentiation agents, and gene therapy are covered briefly as well.
• Commentary (Mazzaferri)
Part 1 of this two-part article describes in detail the distinct types of thyroid cancer, as well as risk factors, outcomes, and prognostic factors, with a focus on thyroid cancers of follicular cell origin.
A 45-year-old woman presented with severe back pain. After radiological and physical examination, the patient was found to have nephrolithiasis with marked hypercalcemia. In addition, a palpable mass in the right side of the neck was encountered. Surgical resection of the mass was performed.
A 28-year-old male has suffered from fever of unknown origin, high blood pressure, diarrhea, and rapid heart rate for several years. Examination revealed enlarged cervical lymph nodes and thyroid nodularity. A biopsy was taken, as were several blood tests. After determining he carried a specific genetic mutation he was diagnosed with Sipple syndrome (MEN-2B).
A 21-year-old woman developed the photosensitive facial rash depicted along with polyarticular arthralgias. Laboratory investigation revealed anemia, leukopenia, a positive antinuclear antibody test (1:1024), and the presence of anti–double-stranded DNA antibodies.
Data presented at ASCO from the phase III DECISION trial showed treatment with the TKI sorafenib (Nexavar) delayed disease progression by 5 months in... More »
The US Food and Drug Administration (FDA) has approved cabozantinib (Cometriq) for the treatment of metastatic medullary thyroid cancer, a rare type... More »
A new study shows that obese patients are more likely to have advanced papillary thyroid cancer and for the cancer to be of an aggressive subtype. More »
SPECT/CT, commonly used for imaging thyroid cancer after radioiodine therapy, was used before therapy to better identify and characterize the cancer. More »
Like Burnison and Lim, we conclude conveying our sense of optimism that progress is being made—and that important clinical questions are being asked... More »
Key Differences between FQHCs and RHCs Chastity Werner, RHIT, June 13, 2013 FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice Susanne Madden, June 12, 2013 Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices Ericka L. Adler, June 12, 2013 Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
iPad Alternatives for Mobile Physicians Marisa Torrieri, June 11, 2013 As more physicians are seeing the merits of media tablets, the market is expanding, too.